Molecular Inventory vs Intangible Assets Analysis
MOLN Stock | USD 3.60 0.47 11.55% |
Molecular Partners financial indicator trend analysis is infinitely more than just investigating Molecular Partners recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Partners is a good investment. Please check the relationship between Molecular Partners Inventory and its Intangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Inventory vs Intangible Assets
Inventory vs Intangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Partners Inventory account and Intangible Assets. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Molecular Partners' Inventory and Intangible Assets is -0.27. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Molecular Partners AG, assuming nothing else is changed. The correlation between historical values of Molecular Partners' Inventory and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Molecular Partners AG are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Inventory i.e., Molecular Partners' Inventory and Intangible Assets go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Inventory
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most indicators from Molecular Partners' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Molecular Partners' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 2nd of June 2024, Enterprise Value Over EBITDA is likely to grow to 1.22, while Selling General Administrative is likely to drop about 12.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 548K | 605K | 49K | 46.6K | Depreciation And Amortization | 2.7M | 3.5M | 2.4M | 2.1M |
Molecular Partners fundamental ratios Correlations
Click cells to compare fundamentals
Molecular Partners Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Partners fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 104.9M | 187.5M | 172.7M | 262.3M | 198.4M | 193.3M | |
Other Current Liab | 7.0M | 10.7M | 12.5M | 8.6M | 8.5M | 6.9M | |
Total Current Liabilities | 28.6M | 57.7M | 46.9M | 17.3M | 14.4M | 13.7M | |
Total Stockholder Equity | 54.1M | 107.2M | 107.3M | 235.2M | 176.4M | 137.3M | |
Property Plant And Equipment Net | 4.2M | 9.4M | 8.1M | 7.2M | 5.7M | 4.7M | |
Current Deferred Revenue | 18.3M | 42.9M | 28.3M | 6.4M | 4.3M | 4.1M | |
Net Debt | (73.2M) | (126.5M) | (65.8M) | (83.1M) | (183.2M) | (192.4M) | |
Retained Earnings | (130.9M) | (195.2M) | (251.0M) | (127.8M) | (191.8M) | (182.2M) | |
Accounts Payable | 2.0M | 2.8M | 4.9M | 997K | 410K | 389.5K | |
Cash | 75.7M | 133.7M | 71.8M | 87.9M | 186.9M | 103.0M | |
Non Current Assets Total | 5.0M | 9.7M | 8.5M | 7.5M | 5.9M | 5.0M | |
Cash And Short Term Investments | 95.1M | 173.7M | 132.8M | 249.1M | 186.9M | 175.8M | |
Net Receivables | 2.5M | 2.8M | 25.7M | 1.7M | 1.7M | 1.7M | |
Common Stock Total Equity | 2.1M | 2.1M | 2.2M | 2.9M | 3.4M | 2.3M | |
Common Stock Shares Outstanding | 21.4M | 25.0M | 31.0M | 33.3M | 32.8M | 26.0M | |
Liabilities And Stockholders Equity | 104.9M | 187.5M | 172.7M | 262.3M | 198.4M | 193.3M | |
Non Current Liabilities Total | 22.2M | 22.7M | 18.5M | 9.8M | 7.5M | 7.1M | |
Inventory | (51.6M) | (486K) | (199K) | (86.7M) | (78.1M) | (74.2M) | |
Other Current Assets | 2.8M | 1.5M | 92.4M | 3.9M | 3.8M | 3.6M | |
Other Stockholder Equity | 182.8M | 299.5M | 355.0M | 360.3M | 364.5M | 250.9M | |
Total Liab | 50.8M | 80.3M | 65.4M | 27.1M | 21.9M | 40.7M | |
Property Plant And Equipment Gross | 4.2M | 9.4M | 20.9M | 21.9M | 22.0M | 23.1M | |
Total Current Assets | 99.9M | 177.8M | 164.2M | 254.8M | 192.5M | 188.3M | |
Intangible Assets | 772K | 347K | 330K | 271K | 212K | 245.5K | |
Common Stock | 2.2M | 2.9M | 3.2M | 3.6M | 3.6M | 2.7M | |
Short Term Investments | 19.4M | 40M | 61M | 161.2M | 119.6M | 125.6M | |
Other Liab | 20.9M | 16.6M | 13.7M | 6.2M | 5.6M | 5.3M | |
Net Tangible Assets | 53.4M | 106.9M | 107.0M | 234.9M | 270.1M | 283.6M | |
Net Invested Capital | 54.1M | 107.2M | 107.3M | 235.2M | 176.4M | 139.6M | |
Net Working Capital | 71.3M | 120.1M | 117.3M | 237.5M | 178.0M | 152.3M | |
Property Plant Equipment | 4.2M | 9.4M | 8.1M | 7.2M | 8.3M | 5.9M | |
Capital Stock | 2.2M | 2.9M | 3.2M | 3.6M | 3.6M | 3.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.215 | Quarterly Revenue Growth (0.62) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.